H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Relay Therapeutics (RLAY) to $16 from $20 and keeps a Buy rating on the shares. The firm says the Lirafugratinib out-licensing agreement “appears heavily back end-loaded.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics, Elevar Therapeutics enter licensing agreement
- Relay Therapeutics price target raised to $20 from $19 at H.C. Wainwright
- Relay Therapeutics Reports Q3 2024 Results and Advances
- Relay Therapeutics reports Q3 EPS (63c), consensus (77c)
- Relay Therapeutics participates in a conference call with JPMorgan